Status:
COMPLETED
A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder
Lead Sponsor:
Janssen, LP
Conditions:
Schizophrenia
Diabetes Mellitus
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to assess and compare how risperidone and olanzapine, two antipsychotic medications, affect the regulation of glucose (sugar) in the body.
Detailed Description
The newer antipsychotic medications risperidone and olanzapine effectively treat schizophrenia and related disorders, and they may cause fewer side effects than the older antipsychotic drugs do. Howev...
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia or related disorder
- stable with respect to disease symptoms and other medical conditions
- would benefit from this type of antipsychotic drug
- if female, using birth control.
Exclusion
- Patients who are delirious, bipolar, severely mentally retarded, or suicidal
- psychiatric diagnosis of disease unrelated to schizophrenia
- presence of stroke, brain tumor, Parkinson's Disease, or diseases that affect blood glucose control
- history of diabetes
- long or recent history of taking risperidone, olanzapine, quetiapine, clozapine, or investigational drugs
- recent history of unstable thyroid function
- if female, not using birth control
- abusing drugs or alcohol.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2003
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT00236379
End Date
August 1 2003
Last Update
May 17 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.